A 33-year-old GII/P0 was examined at 14 + 2 weeks gestation. In addition to one eutrophic fetus with a normal placenta a second amniotic cavity with honeycomb-like structure was found (60 × 32 mm), so that a diagnosis of CMCF was suspected (Figs. 3 and 4). Metastases were excluded clinically. The beta hCG level fell continuously from the 17th week of gestation onwards (Fig. 1). No signs of preeclampsia, HELLP syndrome or hyperthyroidism were detected under close observation.

The suspected diagnosis was confirmed at caesarean section, which was performed without delay at 31 + 4 weeks gestation in view of heavy vaginal bleeding most probably due to early premature placental abruption. A male infant weighing 1900 g was delivered with Apgar scores of 7/8/9 at 1, 5 and 10 minutes. Arterial pH = 7.35, venous pH = 7.37 and base excess was −0.4; decision-to-delivery time was 10 minutes. The pathology showed an almost completely necrotic hydatidiform mole (Figs. 2 and 5) without evidence of choriocarcinoma. Maternal haemoglobin was 10.3 g/dl postoperatively compared to a preoperative level of 13.2 g/dl.
An individualised follow-up schema was agreed on and at 2 months post partum a rise in serum beta hCG was noted. A repeat curettage was thus performed, the removed specimen showing only regressive placental villi without molar tissue. A rising hCG level was again noted at 8 months post partum and this time two doses of methotrexate (1 mg/kg 14 days apart) were administered. Despite this initial treatment serum hCG remained raised and a repeat curettage was performed. Choriocarcinoma was excluded on histology. Under close observation serum hCG values have since remained undetectable.

**Discussion**

Twin pregnancy consisting of one fetus and one complete mole (CMCF, complete hydatidiform mole and a coexistent fetus) is a rare occurrence in obstetrics with an incidence of 1/22 000 to 1/100 000 pregnancies [1].

---

**Fig. 1** Serum beta hCG in the course of treatment.

**Fig. 2** Macroscopic picture of the hydatidiform mole.

**Fig. 3** Transverse sonographic view of the fetal abdomen adjacent to mole-like tissue.

**Fig. 4** Hydatidiform mole with reduced perfusion on Doppler ultrasound.
Diagnosis is mostly made on ultrasound, usually between the 12th and 14th weeks of pregnancy [1, 2], however despite advances in obstetric and gynaecological ultrasound the detection rate reported in the literature is only about 68% [3]. MRI offers a useful imaging alternative [4, 12] and promising results have been published with the use of [18 F]Fluorodeoxyglucose-positron-emission-tomography in combination with CT [5]. A distinction is made between partial and complete moles. Partial moles contain a triploid set of chromosomes and are the result of dispermatic fertilisation of a haploid oocyte. Complete moles consist of 46 paternal chromosomes and do not have any fetal structures [3].

Three disease entities must be considered in the differential diagnosis when a mole-like placenta is suspected together with a viable fetus: a singleton pregnancy consisting of a partial mole and one viable fetus; a twin pregnancy with a complete mole and one viable twin with a separate placenta; and a combination of a partial mole with a twin in one amniotic sac, and one “normal” twin in the other [3].

When a partial mole is present the fetus involved is almost always triploid so that termination of pregnancy should be considered. On the other hand a diploid karyotype does not provide diagnostic certainty since diploid partial moles have been described [2].

Since the genotype origin of complete moles is entirely paternal the chromosomal origin should be determined. PCR techniques to detect DNA polymorphisms in molar tissue can show uniparental disomy either through exclusion of maternal alleles or on comparison with paternal alleles [2].

Continuation of pregnancy is possible when a complete mole together with a normal coexisting twin is diagnosed [3]. Such pregnancies are associated with increased risks of prematurity, intrauterine death, vaginal bleeding, preeclampsia, hyperthyroidism, theca lutein cysts, uterine rupture and the development of malignant neoplasia, i.e. a trophoblastic tumour (GTD, persistent gestational trophoblastic disease), which is thought to be the most common complication [1,3,6].

Another important diagnosis to be considered in differential diagnosis is placental mesenchymal dysplasia, which, in contrast to molar pregnancies, carries no malignancy risk and, interestingly, is associated with Beckwith-Wiedemann syndrome in up to 25% of cases. Mesenchymal dysplasia is often characterised by dilated vessels and associated fetal growth restriction [7].

A possible explanation for the increased risk of vaginal bleeding is that molar implantation usually occurs in the lower uterine segment [8]. The risk factors for the occurrence of this disease entity have not yet been clearly defined although a number of studies report a disproportionately high number of twin pregnancies with complete mole and coexisting fetus (approx. 22%) following reproductive medical intervention, e.g. ovarian stimulation [1,3].

When the pregnancy is not terminated the overall likelihood of a live birth is between 16 and 56% [1, 3]. Morocolles et al. put the live birth rate at 40% in the event of pregnancy being sustained beyond the 14th week of gestation [8], and Shaik et al., in a case report from 2015, state a 40% probability of early pregnancy loss together with a 25% chance of a live birth [9]. In a comprehensive review from 2015 including 177 cases Rohilla et al. state a live birth rate of 37% [10].

On average children are delivered in the 30th week of gestation. When one considers all molar pregnancies together, termination of pregnancy occurs on average in the 16th week [1].

The FIGO (Fédération Internationale de Gynécologie et d’Obstétrique) classification of GTD is essentially based on localisation (FIGO I: uterus; FIGO II: outside of the uterus but in the genital area; FIGO III: lungs; FIGO IV: all other localisations). The modified, prognostically relevant scoring system incorporates the patient’s age, the interval between current and previous pregnancy, the hCG level before commencement of treatment, tumour size, size and number of metastases and, if applicable, a history of previous unsuccessful chemotherapy [1].

In most cases GTD following CMCF can be adequately treated with monochemotherapy [1].

Free and total beta hCG levels are extremely high with a peak at the beginning of the 2nd trimester [8]. Alpha fetoprotein (AFP) is usually raised in patients with a complete mole but can be normal in the presence of CMCF, whereas pregnancy-associated plasma protein A (PAPP-A) and pregnancy-specific beta 1 glyco-
protein (SP1) are raised in both cases [2]. In our case PAPP-A and AFP levels were not determined in view of obvious laboratory and clinical findings.

Constant beta hCG monitoring is of clinical importance in order to assess the extent of the pathology and the associated risk of complications. In our case continuation of pregnancy was justified in the presence of continuously falling hCG levels from the 17th week of gestation onwards.

In a large observational study including 77 patients with CMCF Sebire et al. reported termination of pregnancy in 10 cases before the 14th week, and in 5 cases between the 15th and 22nd weeks of gestation.

A further 2 of the 53 pregnancies that were initially continued were subsequently terminated before 24 weeks gestation due to early preeclampsia. 23 (43%) patients had an abortion or an intrauterine fetal death before 24 weeks gestation. 28 women delivered in or after the 24th week of gestation. In this group there were 20 (38%) live births, 7 intrauterine deaths and one neonatal death.

Only one case of severe preeclampsia and one of pulmonary embolus were reported. Fifteen patients developed persistent GTD (19%), and three of these patients terminated pregnancy within the first trimester. Eleven of these 15 patients were treated curatively with monochemotherapy (73%) and 4 required combination chemotherapy [11].

Clinical Bottom Line

Twin pregnancy consisting of one fetus and one complete mole is a rare obstetric finding that presents a challenge to both the treating obstetrician and the patient and requires an open discussion of outcomes when deciding on a treatment strategy. The detection rate is low and doctors working in antenatal medicine in particular should be sensitised to the diagnosis to enable adequate assessment for possible risk factors such as premature birth, intrauterine death, vaginal bleeding, preeclampsia, hyperthyroidism, theca lutein cysts, uterine rupture and trophoblastic tumours. As this case illustrates, under close observation continuation of pregnancy can be considered.

Conflict of Interest

None.

References

12 Herek D, Karabulut N. The role of magnetic resonance imaging in the diagnosis of complete hydatidiform mole in a twin pregnancy. Int J Gynaecol Obstet 2013; 123: 77